natgillin/translations-raw huggingface dataset:
A compound according to [1] or [2] or a salt thereof, wherein R1 is a C1-C6 alkyl group, a C1-C6 alkanoyl group which may be substituted with one or more halogen atoms, or a hydrogen atom. 
Tvar u skladu s patentnim zahtjevom 1 ili 2 ili njena sol, pri čemu je R' C,-C4 alkilna skupina, C;-C; alkanoil skupina koja može biti supstituirana s jednim ili više atoma halogena, ili atomom vodika.
separating the A9-tetrahydrocannabinol from the resulting phase containing the A9-tetrahydrocannabinol; and 
(b) razdvajanjem A*-tetrahidrokanabinola iz dobivene faze koja sadrži A*-tetrahidrokanabinol; i
reacting a compound of formula (2a): or a salt thereof, with a sulfonating agent to form a compound of formula (IV): or a salt thereof; 
reakciju spoja formule (2a): ili njegove soli, sa sredstvom za sulfoniranje, da se dobije spoj formule (IV): ili njegova sol;
70:4646-4654 . In view of the foregoing, it will be appreciated that the invention described herein inter alia relates to the following items: An attenuated virus which comprises a viral genome comprising a modified protein encoding sequence having a codon pair bias less than the codon pair bias of a parent protein encoding sequence from which it is derived. 
Oslabljeni virus koji sadrži virusni genom koji sadrži sekvencu koja kodira modificirani protein koja ima pristranost para kodona koja je manja nego pristranost para kodona od matičnog proteina koji kodira sekvencu iz koje je dobiven 1 ima postojeće sinonimne kodone iz matičnog preraspodijeljenom redoslijedu, pri čemu se pristranost para kodona (CPB) izračunava pomoću slijedeće formule
A solids flow control system comprising a plurality of solids control valves of Claim 1. 
Sustav regulacije protoka krutih tvari naznačen time da sadrži mnoštvo regulacijskih ventila za krute tvari prema zahtjevu 1.
The bispecific antibody of claim 9, wherein said H/L chain combination that binds a tumor-antigen binds CLEC12A. 
Bispecifično protutijelo sukladno patentnom zahtjevu 7, naznačeno time, da spomenuta kombinacija H/L lanca koja veže tumorski antigen veže CLEC12A.
an outer tube configured to be fixed at the top to a bottom wall of a tank extending through the inner cavity of the body and projecting downward relative to the body; 
stroja namijenjenog da sadrži tekućine kojima će se puniti boce, pruža se kroz unutarnju šupljinu (18) tijela (12) i pruža se premaa dolje u odnosu na tijelo (12);
As the composition is characterised by a specific water content as given above, its components, in particular their amount and their water content, and the way of processing them to the composition are selected such that the desired water content is achieved in the composition. 
S obzirom da je pripravak karakteriziran specifičnim udjelom vode kako je prethodno definirano, njegovi sastavni dijelovi, posebno njihova količina odnosno količina vode u njima, te način na koji su pripremljeni u pripravku, odabrani su tako da se u pripravku postigne željena količina vode.
In some examples, the breechblock slide 37 includes the first recess 39 of which includes at least one recess section 41, 43 formed on a lateral surface and/or upper surface of the breechblock slide 37 and running transverse to its longitudinal axis. 
Klizač zatvarača (37) prema patentnom zahtjevu 4, naznačen time, da njegovo prvo udubljenje (39) obuhvaća barem jedan odsječak udubljenja (41, 43), oblikovan na postranoj plohi i/ili gornjoj strani klizača zatvarača (37) 1 prolazi poprečno na uzdužnu os klizača.
A hand held medicine dosing and dispensing device according to any preceding claim wherein one of the cassette and the housing includes latch members in the form of elongate projections engageable, when the cassette is received within the housing, with latch members in the form of corresponding openings provided in the other of the cassette and the housing, and the dosing and dispensing device further includes one or more biasing members to bias each of the elongate projections into engagement with the corresponding opening when the cassette is received within the housing. 
Ručni uređaj za doziranje i izdavanje lijeka prema bilo kojem prethodnom zahtjevu naznačen time da jedna kaseta i kućište sadrže elemente zasuna u obliku duguljastih izbočenja koja se, kada se kaseta prihvaća unutar kućišta, mogu zahvatiti s elementima zasuna u obliku odgovarajućih otvora koji su predviđeni u drugoj kaseti i kućištu, te uređaj za doziranje 1 izdavanje nadalje sadrži jedan ili više potisnih elemenata za potiskivanje svakog od duguljastih izbočenja u zahvat s odgovarajućim otvorom kada se kaseta prihvaća unutar kućišta.
is H, F, Cl, CH3 or OCH3, or a pharmaceutically acceptable salt thereof. 
R*je H,F, CI, CH; ili OCH; ili njegova farmaceutski prihvatljiva sol.
The solid formulation according to any one of claims 2 to 4, characterized in that the disintegrant/carrier is selected from the group consisting of lactose, starch, cellulose, microcrystalline cellulose and methylcellulose, preferably characterized in that the carriers are starch and lactose. 
Čvrsta formulacija prema patentnom zahtjevu 2 ili 4, naznačena time, da je dezintegrator/nosač odabran iz skupine koja se sastoji od laktoze, škroba, mikrokristalne celuloze i metilceluloze, a poželjno je naznačena time, da nosači su škrob 1 laktoza.
a VH chain region comprising an amino acid sequence having the formula: FRH1-CDRH1-FRH2-CDRH2-FRH3-CDRH3-FRH4, wherein FRH1 consists of any one of SEQ ID NOs: 60 to 66; CDRH1 consists of any one of SEQ ID NOs: 117 to 122; FRH2 consists of any one of SEQ ID NOs: 67 to 75; CDRH2 consists of any one of SEQ ID NOs: 123 to 134; FRH3 consists of any one of SEQ ID NOs: 76 to 90; CDRH3 consists of any of SEQ ID NOs: 135 to 141; and FRH4 consists of any one of SEQ ID NO: 91 to 92. 
VH područje lanca, koje sadrži aminokiselinski slijed s formulom: FRH1-CDRH1-FRH2-CDRH2FRH3-CDRH3-FRH4, gdje se FRH1 sastoji od bilo kojeg od SEQ ID NO: 60 do 66; CDRH1 se sastoji od bilo kojeg od SEQ ID NO: 117 do 122; FRH2 se sastoji od bilo kojeg od SEQ ID NO: 67 do 75; CDRH2 se sastoji od bilo kojeg od SEQ ID NO: 123 do 134; FRH3 se sastoji od bilo kojeg od SEQ ID NO: 76 do 90; CDRH3 se sastoji od bilo kojeg od SEQ ID NO: 135 do 141; i FRH4 se sastoji od bilo kojeg od SEQ ID NO: 91 do 92.
the share of the inertial forces compensated by said one-dimensional or bi-dimensional flexible elements is at least 70%, the residual share being discharged onto the load bearing structure; 
- dio inercijskih sila koje kompenziraju navedeni jednodimenzijski ili dvodimenzijski fleksibilni elementi je u najmanju ruku 70%, dok ostatak odlazi u nosivu strukturu;
In the embodiment shown, there are two latch keys 16 arranged at 180 degree intervals about the pitch circle defined by the cylindrical lower end 13 a . 
U pokazanom primjeru postoje dvije zasuna 16 postavljene u intervalu od 180% oko kruga definiranog od strane cilindričnog donjeg kraja 13a.
An apparatus for transmitting broadcasting signal, the transmitter comprising: means for converting a transport stream to a Physical Layer Pipe, PLP and generating a data slice including the PLP; means for allocating symbols for the data slice to a signal frame and arranging layer-1 information and layer-2 information in the signal frame, the layer-1 information including a data slice identifier for the data slice and a PLP identifier for the PLP, the layer-2 information including a network information table, NIT having a descriptor corresponding to the transport stream in the signal frame, wherein the descriptor includes the PLP identifier, an identifier of a transmission system, information for a tuning frequency of the transmission system, an active Orthogonal Frequency Division Multiplexing, OFDM, symbol duration field and a guard interval field; 
Uređaj za odašiljanje emitiranog signala, odašiljač obuhvaća: sredstva za pretvorbu prijenosnog toka u PLP i dobivanje podatkovnog komada, uključujući PLP; sredstva za dodjeljivanje simbola za podatkovni komad okviru signala i organiziranje informacija sloja 1 1 sloja 2 u okviru signala, informacija sloja 1 obuhvaća identifikator podatkovnog komada za podatkovni komad i identifikator PLP-a za PLP, informacija sloja 2 obuhvaća NIT čiji deskriptor odgovara prijenosnom toku u signalu okvira, gdje deskriptor obuhvaća identifikator PLP-a, identifikator sustava prijenosa, informaciju za tuniranje frekvencije prijenosnog sustava, aktivno polje trajanja OFDM simbola 1 polje zaštitnog intervala; sredstva za moduliranje (S1705) okvira signala pomoću OFDM metode; i sredstva za odašiljanje (S1707) moduliranog okvira signala.
With this arrangement a seal 79, such as an elastic ring, surrounds the chamber 73 to provide a liquid-tight seal. 
Uz ovakvu izvedbu brtva 79, kao što je na primjer elastični prsten, okružuje komoru 73 kako bi ostvarila nepropusnu brtvu.
a core comprising a core polymeric material that does not have a pharmaceutical substance; 
jezgru koja sadrži polimerni materijal jezgre bez farmaceutske tvari;
Besides decreasing the yield by the formation of the 7-epi degradant, this impurity requires adding a chromatographic step to remove the impurity. 
Osim smanjenja prinosa formiranjem 7-epi degradanta, ovo onečišćenje zahtjeva dodavanje kromatografskog koraka za uklanjanje onečišćenja.
A suspension according to claim 1, characterized in that riluzole or said pharmaceutically salt thereof is in amounts from 0.1 % to 20% w/v, preferably from 0.2% to 10% w/v, more preferably from 0.3% to 6 % w/v. 
Suspenzija u skladu s patentnim zahtjevom 1, naznačena time što riluzol ili navedena njegova farmaceutska sol dolaze u količinama od 0,1% do 20% tež./vol., po mogućnosti od 0.2% do 10% tež./vol., poželjnije od 0,3% do 6% tež./vol.
The method of any one of claims 1 to 10, wherein the (±)-A9-tetrahydrocannabinol comprises at least about 95% by weight, preferably at least about 98% by weight and more preferably at least about 99% by weight of trans-(-)-A9-tetrahydrocannabinol and trans-(+)-A9-tetrahydrocannabinol based on the total amount of cannabinoids. 
Postupak prema bilo kojem od zahtjeva 1 do 14, naznačen time da (±)-A9-tertahidrokanabinol sadrži barem 95%, poželjno barem 98%, poželjnije barem 99% težinski trans-(-)-A9-tertahidrokanabinola i trans-(+)-A9-tertahidrokanabinola u odnosu na ukupnu količinu kanabinoida.
In DE 19533168 and US 4,877,838 the reactive diluents consist of esters containing reactive epoxide groups either in the fatty acid or the alcohol moiety. 
U DE 19533168 i US 4,877,838 reaktivna sredstva za razrjeđivanje se sastoje od estera koji sadrže reaktivne epoksidne skupine u masnoj kiselini ili u skupini alkohola.
The formulation according to claim 1 wherein the compound of Formula (I) is selected from the group consisting of: 
Spoj prema patentnom zahtjevu 1, izabran iz grupe koja sadrži:
A pharmaceutical composition comprising a therapeutically-effective amount of the antibody polypeptide of any one of claims 1-7 and a pharmaceutically acceptable carrier. 
Farmaceutska kompozicija koja sadrži terapijski efikasnu količinu polipeptida antitijela bilo kojeg od patentnih zahtjeva 1-7 1 farmaceutski prihvatljiv nosač.
CLDN6 is associated with the surface of a cell if it is located at the surface of said cell and is accessible to binding by CLDN6-specific antibodies added to the cell. 
Antitijelo suglasno zahtjevu 1, koje je sposobno da se veže za CLDNG6 asociran na membrani stanice koja eksprimira CLDNS6 i koje u biti nije sposobno da se veže za CLDNO.
at least 95%, at least 97%, at least 99%, at least 99.5% or more) in the DLS spectrum. 
barem 95%, barem 97%, barem 99%, barem 99,5% ili više) u DLS spektru.
A compound of Formula 1, a tautomer thereof or a pharmaceutically acceptable salt of the compound or tautomer, wherein: 
| = O (No ps zh pi njegov tautomer ili farmaceutski prihvatljiva sol spoja ili tautomer, pri čemu:
A computer program comprising instructions for carrying out all the steps of the method according to any preceding method claim, when said computer program is executed on a computer system. 
Računalni program koji sadrži upute za provođenje svih koraka postupka prema bilo kojem od prethodnih Zahtjeva, kada je navedeni računalni program proveden na računalnom sustavu.
The sustained release composition of claim 4, wherein the biocompatible polymer is purified 50:50 poly(lactide-co-glycolide). 
Oblik za produljeno oslobađanje prema zahtjevu 4, gdje je biokompatibilni polimer pročišćeni 50:50 poli(laktidkoglikolid).
a light chain variable region, wherein the CDRL1 comprises the amino acid sequence of SEQ ID NO:15, the CDRL2 comprises the amino acid sequence of SEQ ID NO:27, the CDRL3 comprises the amino acid sequence of SEQ ID NO:35, and a heavy chain variable region wherein the CDRH1 comprises the amino acid sequence of SEQ ID NO:47, the CDRH2 comprises the amino acid sequence of SEQ ID NO:57, and the CDRH3 comprises the amino acid sequence of SEQ ID NO:91; or 
Izolirano anti-IL-6 antitijelo koje sadrži: aminokiselinsku sekvencu varijabilne regije lakog lanca označenu Identifikacijskim brojem sekvence (SEQ ID NO): 101 i aminokiselinsku sekvencu varijabilne regije teškog lanca označenu kao SEQ ID NO: 103;
The method according to claim 24, wherein Ra1 is selected from hydrogen, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, and halogen. 
Farmaceutski sastav za uporabu prema zahtjevu 2, naznačen time, da je Ra, odabran od sljedećih: vodik, nesupstituirani C,-Cg alkil, nesupstituirani C,-Cg alkoksi i halogen.
An annular space is provided which preferably holds the dispensing tube for connecting the outlet 9 of the container 2 with the dispensing tap 4. 
Predviđen je kružni prostor koji ponajprije drži cijev za točenje za spajanje izlaza 9 iz spremnika 2 s pipcem za točenje 4.
normalizing the migration time(s) to migration time indice(s) based on given standard migration time indice(s) of the standard; 
normaliziranje vremena migracije prema indeksu(ima) vremena migracije na temelju danih standardnih indeksa vremena migracije standarda;
contacting an acid solvate of a compound of formula II: with an amide under conditions suitable for forming an amide solvate of the compound of formula II; and contacting the amide solvate with an aqueous base comprising sodium ions under conditions suitable for forming the compound of formula I. 
TI s amidom pod uvjetima pogodnim za nastajanje amidnog solvata spoja s formulom II; te b) kontaktiranje amidnog solvata s vodenom bazom koja sadrži natrijeve ione pod uvjetima pogodnim za nastajanje spoja s formulom I.
This solution was purified by flash chromatography using an EtOAc/heptane gradient. 
Ova otopina je bila očišćena flash kromatografijom koristeći gradijent EROAc/heptana.
The adhesion promoter in the adhesive composition according to the present invention consists of one or more salts of alkyl ether sulphates, wherein the cation is a cation of organic or inorganic origin and the anion has formula CH3(CH2)mCH2(OCH2CH2)nOSO3- with m varying from 6 to 22, preferably from 8 to 16 and still more preferably equal to 10 and n varying from 1 to 5, preferably equal to 1 or 2. 
Adhezivna kompozicija u skladu sa patentnim zahtjevom 1, pri čemu se adhezivni promoter sastoji od jedne ili više soli alkil eter sulfata, pri čemu kation je kation organskog ili neorganskog porekla a anion ima formulu
The pharmaceutical composition according to claim 12 comprising an amount of 5 to 50 mg of the glucopyranosyl-substituted benzene derivative and an amount of 0.5 to 10 mg of the DPP IV inhibitor. 
Farmaceutski sastav prema zahtjevu 1, 2, 3 ili 4, naznačen time, da sadrži količinu od 5 do 50 mg derivata benzena supstituiranog glukopiranozilom 1 količinu od 0,5 do 10 mg DPP IV-inhibitora.
A composition for protecting an animal from an invertebrate parasitic pest comprising a parasiticidally effective amount of a composition of claim 1 and at least one carrier. 
Kompozicija za zaštitu životinje od štetnog parazitskog beskičmenjaka koja sadrži paraziticidno efikasnu količinu kompozicije prema bilo kojem od patentnih zahtjeva 1 do 6 i najmanje jedan nosač.
Biomaterials as claimed in claim 3, wherein the weight ratio is of 25:75. 
Biomaterijali kako su prijavljeni u patentnom zahtjevu 3, naznačeni time da maseni omjer jest 25:75.
n is 0; is selected from the group consisting of hydrogen, alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, hoteroarylalkyl, and (NRCRD)sulfonyl; and RC and RD are independently selected from the group consisting of hydrogen and alkyl. 
Ry je odabran iz skupine koja se sastoji od vodika, alkila, arilalkila, cikloalkila, cikloalkilalkila, heterocikla, heleroarilalkila, i (NRcRp)sulfonila; a Rc 1 Ry su neovisno odabrani iz skupine koja se sastoji od vodik 1 alkila.
A well as claimed in claim 1, wherein the receiver is an electromagnetic receiver and the signal is an electromagnetic signal. 
Bunar (10) sukladno patentnom zahtjevu 1 i 2, naznačen time, da je prijemnik (360) ili primopredajnik elektromagnetski prijemnik ili primopredajnik (250, 360) respektivno i signal je elektromagnetski signal.
Reduction of the tetrabenazine can be accomplished using an aluminium hydride reagent such as lithium aluminium hydride, or a borohydride reagent such as sodium borohydride, potassium borohydride or a borohydride derivative, for example an alkyl borohydride such as lithium tri-sec-butyl borohydride. 
Redukcija tetrabenazina se može provesti uporabom reagensa aluminij hidrida poput litij aluminij hidrida, ili uporabom reagensa borohidrida poput natrij borohidrida, kalij borohidrida ili derivata borohidrida, na primjer alkil borohidrida poput litij tri-sek-butil borohidrida.
or a mechanism comprising a device, by using an electric signal, configured to modify the position of the maneuvering rods so as to raise or lower the drainage plug and as such control the flow of the water in the drain; 
• ili mehanizam (6A ili 6B-2) koji sadrži o uređaj (6A-2e) koji, pomoću električnog signala, mijenja položaj pogonskih šipki (6A-3 ili 6B-3) za podizanje ili spuštanje čepa za odvod (6B-4) i tako kontrolira odljev vode u odvod;
concentrating the anti-HER2 antibody solution to a concentration of 125 g/l or more with a method selected from diafiltration or tangential-flow filtration, and 
koncentriranje otopine imunoglobulina na koncentraciju od 100 g/l ili više, putem postupka odabranog od diafiltriranja ili filtriranja tangencijalnim protokom; i
A composition according to claim 1 or 2, wherein R1 is methyl. 
Pripravak u skladu sa zahtjevom 1 ili 2, naznačen time, da R1 je metil.
The method of item 12, wherein the tissue sample is a blood sample. 
Način prema zahtjevu 10, naznačen time, što uzorak tkiva jest uzorak krvi.
adding lysis buffer in combination with binding buffer to the sample to obtain a lysed solution; 
(b) dodavanje pufera za lizu s bazičnim pH u kombinaciji s puferom za vezanje uzorku kako bi se dobila lizirana otopina;
Ring A is Ring B is wherein Ring B is optionally substituted with up to 4 fluorine atoms or up to two C1-4alkyl optionally substituted with up to 3 fluorine atoms, up to two OH, or up to two OC1-2alkyl groups; 
ili njegova farmaceutski prihvatljiva sol, gdje je prsten A ili je prsten B ili gdje je prsten B izborno supstituiran sa do 4 atoma fluora, do dva OH ili do dva C1-4alkila koji je izborno supstituiran sa do 3 atoma fluora, do dvije OH ili do dvije OC1-2alkil grupe;
The fan assembly of claim 1, wherein the second member is pivotably connected to the first member. 
Ventilatorski sustav prema zahtjevu 2. gdje je drugi član (300) pivotalno spojen na prvi član (304).
An antibody of the IgG class comprising a polypeptide chain having one or more non-natural amino acid residues at specific sites selected from the group consisting of light chain residue L22 according to the Kabat or Chothia numbering scheme, heavy chain residues H19, H25, H40, H52, and H70 according to the Kabat or Chothia numbering scheme, and heavy chain residues H119, H190, H222, and H241 according to the EU numbering scheme, or a post-translationally modified variant thereof, wherein the post-translational modification is interchain disulphide bonding, intrachain disulphide bonding, N-linked glycosylation, phosphorylation, O-linked glycosylation, methylation, acetylation, lipidation, GPI anchoring, myristoylation or prenylation. 
HR P20190475 T1 PATENTNI ZAHTJEVI Antitijelo IgG klase koje sadrži polipeptidni lanac koji ima jedan ili više ne-prirodnih aminokiselinskih ostataka na specifičnim mjestima odabranih iz grupe koja se sastoji od ostatka 1.7 lakog lanca u skladu sa Kabat ili Chothia shemom numeriranja, ostataka H404, H121, H180, i H136 teškog lanca u skladu sa EU shemom numeriranja, ili njihove post-translacijske modificirane varijante, gdje post-translacijska modifikacija je međulančano disulfidno vezivanje, međulančano disulfidno vezivanje, N-vezana glikozilacija, fosforilacija, O-vezana glikozilacija, metilacija, acetilacija, lipidacija, GPI usidravanje, miristilacija ili prenilacija.
with a buffer, wherein preferably the buffer comprises the phosphate; and 
N H (ID u puferu, gdje pufer sadrži fosfat;
FIG. 1 is an exploded perspective view of a ski boot according to the invention; 
Na crtežima: slika 1 = prikazuje u perspektivi rastavljenu cipelu za skijanje prema izumu; slika 2
The instrument according to claim 6, wherein said fixating member is adapted to assist in the fixation of the inflatable device on the inside of the stomach wall. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što je uređaj prilagođen da bude u najmanju ruku djelomično invaginiran u stijenku želuca međuželučanim kopčama, s vanjske strane stijenke želuca.
The composition of claim 8, wherein the methyl paraben and/or propyl paraben are used in a concentration of about 0.18% w/v and about 0.02% w/v, respectively. 
Sastav prema zahtjevu $, gdje se metil paraben i/ili propil paraben koriste u koncentraciji od oko 0,18 % wfv, odnosno oko 0,02 % w/v.
The residue was dissolved using ethyl acetate (200 ml), the solution washed with water (2 x 50 ml), the organic phase dried over anhydrous magnesium sulphate and after filtration, concentrated under reduced pressure. 
Ostatak se otopi korištenjem etil acetata (200 ml), otopina se ispere vodom (2 x 50 ml), organska faza se suši iznad anhidridnog magnezij sufata i nakon filtriranja se koncentrira uz smanjeni tlak.
The resulting solution was chilled and the precipitated 1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid amide collected by vacuum filtration as a white crystalline solid (0.438g, 2.90 mmol, 65%). 
i miješan preko noći na 95 "C. Rezultirajuća otopina je ohlađena i precipitirani amid 1,4,5,6-tetrahidro-ciklopentapirazol-3-karboksilne kiseline je sakupljen vakuum filtriranjem kao bijela kristalinična krutina (0.438 g, 2.90 mmol, 65%).
Compound 438 has the same structure as compound 4 in Figure 1 except that R3 (-CH2CH2CO2H) is replaced by H. 
Spoj 438 ima istu strukturu ako spoj 4 na Slici 1 osim što je R* (-CH,CH,CO;H) zamijenjen s H.
The antikine antibodies of the invention may be formulated as a composition comprising the antikine antibody or its antigen binding fragments with a carrier, excipient or buffer as described in more detail below. 
Pripravak, naznačen time, da sadrži barem jedno monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, u kombinaciji s nosačem, ekscipijentom ili puferom.
The antibody or antigen binding fragment thereof for the use defined in any one of claims 1 to 16, wherein said antibody or antigen binding fragment thereof is used with an anti-cancer agent. 
Protutijelo ili njegov fragment koji veže antigen za uporabu prema bilo kojem od zahtjeva 1 do 15, naznačeno time, da se navedeno protutijelo ili njegov fragment koji veže antigen, upotrebljava zajedno sa sredstvom protiv raka.
B—width of the box 
A - prethodna dubina kutije
The composition according to claim 5, wherein the other anti-HCV agent is another inhibitor of HCV polymerase. 
Sastav prema zahtjevu 15, naznačen time, da sljedeće anti-HCV-sredstvo je dodatni inhibitor HCV-polimeraze.